menu search

molecular partners to present initial data from ongoing phase 1/2a trial of mp0533 for patients with relapsed/refractory aml and aml/mds at the 65th ash annual meeting and exposition

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR ...

November 2, 2023, 2:00 am

molecular future (mof) showcasing remarkable journey

molecular Future (MOF), a leading digital asset investment service, invites the world to revisit its dy...

November 1, 2023, 6:20 pm

Why is mainz biomed (mynz) stock moving today?

Mainz Biomed (NASDAQ: MYNZ ) stock is on the move Wednesday after the molecular genetics cancer diagno...

November 1, 2023, 8:40 am

Why is cardio diagnostics (cdio) stock up 45% today?

Shares of cardiovascular medicine specialist Cardio Diagnostics (NASDAQ: CDIO ) are skyrocketing on Tuesday following the announcement of a key deal. ...

October 31, 2023, 3:56 pm

Context therapeutics reveals ‘encouraging' preclinical data for ctim-76 tumor treatment

Context Therapeutics (NASDAQ:CNTX) Inc has announced what it called encouraging preclinical data regarding its preclinical asset, CTIM-76, a Claudin 6...

October 31, 2023, 10:12 am

Dmtk shareholders: contact robbins llp for information regarding the class action against dermtech, inc.

SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) — Robbins LLP reminds investors that a shareholder filed a class action lawsuit on behalf of persons and e...

October 30, 2023, 10:19 pm

molecular partners interim management statement q3 2023: continued validation seen across the …

Financial and Business Outlook For the full year 2023, at constant exchange rates, the Company expects total expenses of CHF 65-70 million, of which a...

October 26, 2023, 9:14 pm

Monte rosa therapeutics announces $25 million registered direct offering, priced at- the-market under nasdaq rules

BOSTON, Oct. 26, 2023 (GLOBE NEWSWIRE) — Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel ...

October 26, 2023, 8:30 pm

Clarkson professors awarded $749,000 usda grant to develop technology to remove phosphate from agricultural fields and prevent nutrient pollution

Potsdam, NY, Oct. 25, 2023 (GLOBE NEWSWIRE) — Silvana Andreescu, Egon Matijevic Endowed Chair Professor of Chemistry and Bio...

October 25, 2023, 5:22 pm

Moderna and caris life sciences partner to develop mrna oncology therapeutics

Moderna Therapeutics Inc (NASDAQ:MRNA) has teamed up with Texas-headquartered private precision medicine and m...

October 24, 2023, 10:21 am

Transplant diagnostics market surges at 7.2% cagr towards usd 8.3 billion by 2032 | market.us

In 2022, molecular assays led in technology, reagents topped product & service, solid organ transplants...

October 19, 2023, 1:52 pm

Clarkson university researchers awarded nysp2i grant to develop sustainable food packaging and present at “keep it fresh!” symposium

POTSDAM, NY, Oct. 18, 2023 (GLOBE NEWSWIRE) — Silvana Andreescu, Egon Matijević Endowed Chair of Chemistry and Bio...

October 18, 2023, 5:13 pm

Here's why you should retain qiagen (qgen) stock for now

Investors are optimistic about QIAGEN's (QGEN) growth in the molecular diagnostics business and the lat...

October 18, 2023, 12:02 pm

Shareholder alert: robbins llp informs shareholders of class action filed against dermtech, inc. (dmtk)

SAN DIEGO, Oct. 16, 2023 (GLOBE NEWSWIRE) — Robbins LLP informs investors that a shareholder filed a class action lawsuit on behalf of persons and e...

October 17, 2023, 3:05 am

Biontech to present multiple program updates across modalities at esmo congress 2023

MAINZ, Germany, October 16, 2023 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present data across its oncology pipeline, c...

October 16, 2023, 3:30 am

Coherus announces toripalimab data at 2023 aacr-nci-eortc international conference on molecular targets and cancer therapeutics

— Data demonstrate preclinical potent T cell activation and differentiated mechanism of action and enhanced clinical efficacy irrespective of PD-L1 ...

October 14, 2023, 4:30 pm

Cogent biosciences presents preclinical data highlighting precision oncology pipeline at the 2023 aacr-nci-eortc international conference on molecular targets and cancer therapeutics

– Novel selective and reversible FGFR2 inhibitor exhibits strong potency across key primary and resistance driver mutations with potential advantage...

October 14, 2023, 4:30 pm

Prelude announces multiple clinical and preclinical poster presentations at aacr-nci-eortc international conference 

WILMINGTON, Del. and BOSTON, Oct. 14, 2023 (GLOBE NEWSWIRE) — Prelude Therapeutics Incorporated (“Prelude”) (Nasdaq: PRLD), a clinical-stage pre...

October 14, 2023, 4:30 pm

Olema oncology kat6 inhibitor compounds demonstrate potent anti-tumor activity

Preclinical data to be presented at the 2023 AACR-NCI-EORTC International Conference on molecular Targe...

October 12, 2023, 11:01 am


Search within

Pages Search Results: